main of the receptor activates the TRADD proteins, which in turn recruit receptor-interacting proteins and lead to apoptosis. 36, 40, 44 Perhaps such activation corresponds to a concurrent activation of NIK and direct NF-B activation. As the cytosolic NF-B concentration rises, the expression of several antiapoptotic genes is amplified. 37 Candidate antiapoptotic genes for NF-B induction include manganese superoxide dismutase, c-IAP2, A20, BCL2, BCLXL, XIAP, and ␥-GCS.
As seen in other cell systems, TNF-induced NF-B activation in astrocytoma cells may be mediated by the TRAF family, which consists of a group of six adapter proteins (TRAF1-TRAF6) that participate in the intracellular signaling activity of several members of the TNFR superfamily. 14, 18 Through appropriate ligand stimulation of TNFRs found on the surface of these cells, TRAF proteins can induce activation of NF-B, resulting in both cytokine secretion and resistance to apoptosis. 14, 17, 20, 38, 46 Investigation of TRAF protein expression in human glioma cells has never been performed, however, and data in other mammalian tumors are scant.
In this investigation, we examined whether constitutive deregulated NF-B activity and expression of TRAF1 and TRAF2 are characteristic features of human astrocytoma cells obtained from WHO Grades II to IV tumor samples. 24 As part of our evaluation, we also compared the intensity of NF-B activity with tumor grade and with the expression of TRAF1 and TRAF2, the activated aspartate-specific cysteinyl protease or caspase 3 (identified as being a key mediator in apoptosis of mammalian cells), 41 and the molecule TANK/I-TRAF (a regulator of TRAF activity in human gliomas).
Materials and Methods

Patient Population
This study included tumor samples histologically verified as Grades II to IV astrocytomas that were obtained in adult patients who had undergone craniotomy for microsurgical tumor removal at the Neurosurgical Clinic, University of Messina School of Medicine. All tumors were located in the supratentorial compartment. Only patients who had undergone extensive gross-total resection of the neoplasm (Ͼ 95% of the tumor volume) were eligible to participate in the study. Patients with AAs and GBMs were treated using both chemotherapy (temozolomide) and fractionated whole-brain radiotherapy (60 Gy) following microsurgical lesion removal. Patients with
LGAs did not undergo postsurgical chemo-or radiotherapy. Samples obtained during single or multiple stereotactic biopsy procedures were not included in the present study. We carefully excluded tumors containing oligodendroglial components, recurrent tumors, and patients who had undergone adjuvant therapy (radio-and/or chemotherapy) before surgery. Furthermore, five samples of normal brain tissue were used as controls.
The tumor samples were resected in 16 men and 11 women whose mean age was 58.9 Ϯ 16.6 years at surgery (range 31-81 years). Table 1 summarizes demographic and laboratory data in the patients in whom the 27 biopsy specimens were obtained. The KPS scores in these patients ranged from 60 to 100 (mean value 88.9 Ϯ 13.7). According to the revised WHO classification, 24 tumors were diagnosed as LGA (seven patients), AA (nine patients), and GBM (11 patients). Patients with LGAs had a mean age of 38.6 Ϯ 4.7 years, a KPS score of 100, and a survival period longer than 208 weeks. Patients with AAs had a mean age of 64.2 Ϯ 14.7 years, a mean KPS score of 84.4 Ϯ 16.7, and a mean survival period of 110.9 Ϯ 18.2 weeks. Patients with GBMs had a mean age of 67.6 Ϯ 11.5 years, a mean KPS score of 85.5 Ϯ 12.1, and a mean survival period of 58.3 Ϯ 15.7 weeks. The total duration of follow up was 208 weeks postsurgery.
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We obtained 27 surgical specimens. All tumor tissue samples were obtained from the neoplastic tissue within 15 minutes of surgical removal. Tissue samples were taken from viable areas of tumor, while trying to avoid areas of gross necrosis. Three to seven anatomically separate areas of the tumor were sampled from each resected specimen, with the number of regional specimens obtained in each case determined by the volume of available resected tissue. Multiple sampling was used to match, as accurately as possible, histological and laboratory data and to obtain quantitative data from the most representative regions of each tumor, again while avoiding data from tissue samples with extensive coagulative necrosis or nonneoplastic tissue. Tissue samples for analysis were placed in cryovials and immediately flash frozen in liquid nitrogen in the operating room and stored at Ϫ80˚C. The tissue adjacent to the frozen samples as well as additional tissue obtained from the resection specimens were used for histological typing and grading based on the WHO criteria. 24 Adjacent matching tissue samples for histological analysis were fixed in 10% formalin. The formalin-fixed paraffin-embedded tissue sections were cut and stained with H & E.
Isolation of Nuclear Extracts From Tumor Specimens
Frozen tumor tissues (~ 50 mg) were harvested through homogenization by using a Potter homogenizer (Braun, Melsungen, Germany) in ice-cold hypotonic lysis buffer (10 mM HEPES [pH 7.9], 0.1 mM EGTA, 0.1 mM EDTA, 1 mM DTT; protease inhibitors: 0.5 mM phenyl methylsulfonyl fluoride, aprotinin, pepstatin, leupeptin [10 mg/ml each]; and phosphatase inhibitors: 50 mM NaF, 30 mM b-glycerophosphate, 1 mM Na 3 VO 4 , and 20 mM p-nitrophenyl phosphate). The homogenate was centrifuged for 1 minute at 2000 rpm at 4˚C to eliminate any unbroken tissues. After 20 minutes on ice, 10% Nonidet P-40 (Sigma Chemical Co., St. Louis, MO) was added to the homogenate for a final concentration of 3.125%, and the mixture was vortexed and microfuged (10,000 rpm) for 1 minute at 4˚C. The nuclear pellet was resuspended in ice-cold hypertonic nuclear extraction buffer (20 mM HEPES [pH 7.9], 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, protease inhibitors, and phosphatase inhibitors), incubated on ice for 30 minutes with intermittent vortexing, and microfuged (10,000 rpm) for 10 minutes at 4˚C. The supernatant was collected as nuclear extract and stored at Ϫ20˚C. The concentration of total proteins in the samples was determined using the Lowry method. To estimate possible contamination of the nuclear extracts with cytoplasmic extract, lactate dehydrogenase activity was assessed using quantitative kinetic determination.
Detection of NF-B DNA-Binding Activity by EMSA
Twenty micrograms of nuclear extract were incubated for 30 minutes at room temperature with 50 fmol of biotin-end labeled 45-mer double-strand NF-B oligonucleotide from the HIV-LTR, 5Ј-TTGTTACAAGGGACTTTCCG CTGGGGACTTTCCAGG AG-GCGTGGG-3Ј. Binding reaction was performed using the LightShift Chemiluminescent EMSA kit (Pierce, Milan, Italy), according to the manufacturer's instructions. Bound complexes were separated on 7.5% nondenaturing polyacrylamide gels, blotted onto nylon membrane, and visualized on x-ray film (Kodax, Milan, Italy) by using autoradiography. 29 
Electrophoresis and Immunoblotting of TRAF1, TRAF2, Caspase 3, and TANK/I-TRAF
Approximately 40 mg tumor tissue was homogenized in a glass tube with a Teflon dounce pestle in 15 vol ice-cold triple-detergent saline buffer containing 15 vol ice-cold triple-detergent lysis buffer (20 mM HEPES, 1 mM EDTA, 2 mM EGTA, 150 mM NaCl, 0.1% SDS, 1.0% IGEPAL 40 (Sigma Chemical Co.), and 0.5% deoxycholic acid [pH 7.5]) containing a broad-range protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany). The protein concentration of the tissue homogenates was determined using the Lowry method. Protein-balanced samples were prepared for SDS-PAGE in twofold loading buffer containing 0.25 M Tris (pH 6.8), 0.2 M DTT, 10% SDS, 0.02% bromophenol blue, and 20% glycerol in distilled water. Samples were heated for 10 minutes at 100˚C and centrifuged for 1 minute at 10,000 rpm. Fifty micrograms proteins per line was routinely resolved by SDS-PAGE on 6.5% for 1 hour at 200 V.
Following electrophoresis, separated proteins were laterally transferred to nitrocellulose membranes in transfer buffer containing 0.192 M glycine and 0.025 M Tris (pH 8) with 20% methanol, at a constant voltage of 100 V for 1 hour at 4˚C. Blots were blocked for 1 hour at room temperature in a saturating solution containing 0.9% NaCl, 1% bovine albumin serum, and 0.05% Tween-20.
Immunoblots were probed using mouse monoclonal antibodies against TRAF1, TRAF2, and caspase 3 and goat polyclonal antibody against TANK/I-TRAF (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), which recognized native proteins at different molecular weights. Following a 2-hour incubation with primary antibody (1: 200) at room temperature, blots were incubated with a goat antimouse immunoglobulin G secondary antibody (1:1000) or with a rabbit anti-goat immunoglobulin G (1:1000) for TANK/I-TRAF immunoblotting and were conjugated to horseradish peroxidase at room temperature for 1 hour. Enhanced chemiluminescence reagents (Amersham Biosciences, Buckinghamshire, United Kingdom) were used to visualize immunolabeling on Kodak Biomax ML chemiluminescent film.
Quantifying TRAF1, TRAF2, Caspase 3, and TANK/ I-TRAF Levels
Semiquantitative evaluation of protein levels detected on immunoblotting was performed using computer-assisted densitometric scanning (Kodak 4.04 Digital Imaging System). Data were acquired as arbitrary densitometric units. We used two different negative controls for each blot.
Statistical Analysis
Statistical analysis was accomplished using the unpaired Student t-test to compare the expression levels of TRAF1, TRAF2, caspase 3, and TANK/I-TRAF as quantitated on Western blot analysis and NF-B activity on EMSA in LGAs, AAs, and GBMs. The Spearman nonparametric correlation test was used to assess the correlation among TRAFs, caspase 3, NF-B, and TANK/I-TRAF expression and the other nominal variables (WHO grade and KPS score). The Pearson correlation test was used to obtain correlation values among numerical variables. Commercially available computer software programs (INSTAT, version 3.0, and PRISM, version 4.0; GRAPH-PAD, San Diego, CA) were used to perform the data analysis. A probability value less than 0.05 was considered statistically significant. All values were expressed as the means Ϯ SDs.
Results
The NF-B DNA-Binding Activity
The NF-B DNA-binding activity was detected in nuclear extracts obtained from all tumor samples ( Fig. 1 upper) . Most tumors showed a variation in NF-B DNAbinding activity levels in one to two increments across the three to seven regions analyzed per tumor. In several cases, lower NF-B levels could be attributed to completely necrotic tissue, according to histological assessment of the formalin-fixed tissue sections. In other instances, however, lower NF-B activity levels appeared to correlate with the presence of only a small number of tumor cells. Matching histological sections revealed that the samples with lower NF-B DNA-binding activity levels and fewer tumor cells had been obtained from the infiltrating edge of the neoplasm. These areas contained a higher proportion of nonneoplastic tissue than tumor tissue.
Samples suspected of having large areas of gross necrosis or nonneoplastic tissue were not included in our analysis. Nuclear factor-B activity levels from one to three ar-eas of histologically pure tumor tissue from each specimen were considered for quantitative analysis; we averaged data when multiple samples were selected for measurements. Even in this context we recorded a variation of up to 20% in NF-B activity levels in different areas of the same tumor. These results may reflect a true biological difference in NF-B activity in various glioma populations, even after controlling for necrosis and optimizing tumor samples through histological correlation.
Definitive quantitative data obtained using densitometric analysis of bands revealed that the DNA-binding activity varied among tumor samples, with a mean value of 26.1 Ϯ 13.2% compared with 6 Ϯ 2.6% in normal brain tissue (p = 0.002). In LGAs the DNA-binding activity was a mean 20.8 Ϯ 10.7%; in AAs, 22.1 Ϯ 8.5%; and in GBMs, 33.7 Ϯ 14.1% (Fig. 1 lower) . Results of statistical analysis revealed that the levels of NF-B DNA-binding activity were correlated with the WHO tumor grade (p = 0.01).
Expression of TRAF1
A 51-kD TRAF1 band was evident in all analyzed tumor samples (Fig. 2 upper) . Results of densitometric analysis of the bands revealed that such expression varied among tumor specimens, with a mean value of 991.9 Ϯ 736.9 ADU compared with 191.4 Ϯ 10.8 ADU in normal brain tissue (p = 0.02). The mean TRAF1 expression level in LGAs was 1056.5 Ϯ 940.3 ADU; in AAs, 736.3 Ϯ 23.9 ADU; and in GBMs, 1107.5 Ϯ 798.4 ADU (Fig. 2 lower) . The expression levels of TRAF1 tended to correlate with the NF-B DNA-binding activity, although the correlation was not statistically significant (p = 0.07). No significant correlation with WHO tumor grade was found.
Expression of TRAF2
A 55-kD TRAF2 band was demonstrated in all analyzed tumor samples (Fig. 3 upper) . Findings on densitometric analysis of the bands revealed that such expression varied among tumor samples, with a mean value of 2420.9 Ϯ 1662.7 ADU compared with 189.8 Ϯ 15.9 ADU in normal brain tissue (p = 0.006). The mean TRAF2 expression level in LGAs was 2033.9 Ϯ 1658.5 ADU; in AAs, 2540.3 Ϯ 1732.2 ADU; and in GBMs, 2532.2 Ϯ 1637.4 ADU (Fig.  3 lower) . No significant correlation was found between 
Expression of TANK/I-TRAF
A 53-kD TANK/I-TRAF band was evident in all analyzed tumor samples (Fig. 4 upper) . The TANK/I-TRAF expression varied among tumor samples according to densitometric analysis of bands, with a mean value of 3080.5 Ϯ 2348.6 ADU compared with 191.4 Ϯ 16.4 ADU in normal brain tissue (p = 0.01). The mean TANK/I-TRAF expression level in LGAs was 2916.2 Ϯ 2396.8 ADU; in AAs, 5168 Ϯ 1770.9 ADU; in GBMs, 1607.2 Ϯ 1561 ADU (Fig.  4 lower) . A significant correlation was found between TANK/I-TRAF expression levels and TRAF2 expression (p = 0.01). An inverse correlation was demonstrated between the expression of TANK/I-TRAF and that of NF-B (p = 0.02).
Western Blot Analysis for Caspase 3
A 32-kD caspase 3 band was evident in all analyzed tumor specimens (Fig. 5 upper) . Caspase 3 expression also varied among tumor samples according to densitometric analysis of bands, with a mean value of 963.9 Ϯ 911.3 ADU compared with 286.4 Ϯ 20.6 ADU in normal brain tissue (not significant). The mean caspase 3 expression level in LGAs was 795 Ϯ 328.9 ADU; in AAs, 1595.3 Ϯ 1336.9 ADU; and in GBMs, 559.1 Ϯ 336.8 ADU (Fig. 5  lower) . A significant correlation was found between caspase 3 expression and TRAF2 expression (p = 0.05), and with TANK/I-TRAF expression levels (p = 0.002).
Discussion
The results of this study confirmed the presence of aberrant NF-B DNA-binding activity in human WHO Grades II to IV astrocytomas. Data also revealed a correlation of such activity with tumor grade, even though NF-B activity showed significant variability in relation to the tumor biological and histological heterogeneity. Constitutive expression of TRAF1, TRAF2, and TANK/I-TRAF in these tumors was also detected, indicating that NF-B activity
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Tumor necrosis factor receptor-associated factors and antiapoptosis can be modulated by such factors in diffusely infiltrating astrocytomas.
"Nuclear factor-B" is a generic term for a dimeric transcription factor formed by the hetero-or homodimerization of proteins deriving from a family of genes named REL. 21 The nuclear translocation of NF-B determines the expression of a number of regulators of immune, inflammatory, and acute phase responses. 15, 26 Nuclear factor-B is also implicated in the control of cell proliferation and apoptosis. The constitutive activation of NF-B turned out to be vital for cell maintenance and prevention of cell death in cancer cells. 4, 20 Members of the NF-B /REL gene families have been identified as potential protooncogenes, as in the case of p100/lyt-10 or bcl-3. 4 Indirect evidence also indicates that NF-B/Rel proteins could be directly involved in cell growth control. In particular, the NF-B transactivation potential appears to be linked to signaling that controls cellcycle progression. It has also been shown that cyclin-dependent kinases regulate RelA through interactions with the coactivator p300. 34 Moreover, NF-B controls the expression of a number of growth-promoting cytokines; and an NF-B-like DNA-binding activity is induced during the G0 to G1 transition after serum stimulation. 3 Nevertheless, the main role of NF-B in the cell immortalization process seems to be related to the control of apoptosis. Actually, NF-B protects fibroblasts against TNF␣-induced apoptosis, as demonstrated with cells from RelA-deficient mice. 7 Furthermore, Jurkat or fibroblastic cells underwent enhanced apoptosis after treatment with TNF␣, ionizing radiation, or daunorubicin when nuclear translocation of NF-B was blocked. 28, 45, 47 The mechanism by which apoptosis is blocked by the nuclear translocation of NF-B is related to the expression of a series of antiapoptotic genes. Based on their NF-B-dependent expression and antiapoptotic function, genes encoding for c-IAP1, c-IAP2 (both inhibitors of apoptosis protein), TRAF1, A20, BCL2, BCLXL, XIAP, and ␥-GCS have been proposed as target genes in such a mechanism. 5, 13, 47 An increased NF-B activity in glioma cell lines has been recently reported. 30 Our findings confirmed the presence of aberrant NF-B DNA-binding activity in WHO Grades II to IV astrocytomas surgically removed from humans compared with normal brain tissue. In contrast to cell lines, human gliomas are highly heterogeneous tumors both histologically and biologically. Such biological heterogeneity resulted in significant variability in NF-B activity in histologically similar tumor samples and in a substantial number of outliers in the statistical analysis. Nevertheless, data showed a trend toward the correlation of such activity with tumor grade. The increased NF-B-related transcriptional activity indicated that glioma cells exist in an activated status and that the degree of such abnormal activation does increase progressively with malignancy.
The signaling cascade that leads to the activation and antiapoptotic activity of NF-B is mediated by TNF stimulation, as shown by the experimental evidence that TNF or soluble CD40L induces nuclear translocation of NF-B. 10, 27, 38, 50 The signal transduction mechanism emanating from the TNFR is thought to be mediated by TRAF2, a signaling intermediate that has been shown to be recruited to the cytoplasmic tail of TNFR through a TNFR1/TRADD/TRAF2 interaction. 1, 9, 27, 38 Based on this hypothesis, TNF can either induce apoptosis through FADD (FAS associating protein with death domain) and caspase recruitment or promote survival through TRAF2 recruitment and NF-B induction (Fig. 6) . 1, 7, 9, 27, 28, 38, 45 Accordingly, it is reasonable to speculate that constitutive activation of NF-B in malignant gliomas may be mediated, at least in part, by TNFR/TRAF2-driven mechanisms.
As shown in the present study, glioma cells from the majority of tumor specimens demonstrated moderate to strong expression of TRAF2, and the expression levels were significantly higher compared with those in normal brain tissue (Fig. 3) . Similar findings have been reported in other cancer cells. The expression of TRAF2 is characteristic of Hodgkin and Reed-Sternberg cells 20 and occurs in hepatoma cells. 23 Furthermore, expression levels of signal adapter protein TRAF2 coincide with melanoma resistance to ultraviolet radiation, 19 and TRAF2 genes are upregulated after applying radiation to esophageal squamous cell carcinomas. 8 The fact that TRAF2 is a protein that plays a cytoprotective role has been demonstrated in the premature death of TRAF2-deficient mice because of severe growth retardation and confirmed by TRAF2-deficient cells highly sensitive to TNF-induced cell death. 51 The mechanism of such TRAF2-mediated NF-B activation is not completely un- derstood. Nuclear factor-B is usually kept inactive in the cytoplasm associated with its endogenous inhibitor protein IB (inhibitor of NF-B). The phosphorylation of IB provokes the activation of NF-B and its translocation into the nucleus. Therefore, TRAF2-mediated NF-B activation may involve the direct recruitment of the IB kinase complex in cooperation with receptor interacting protein (Fig.  6) . 6, 16, 22, 35, 51, 52 Alternatively, to activate IB kinase, TRAF2 can associate with several upstream mitogen-activated protein kinases to induce NF-B, including NIK, 42 MAPK1, and MAPK3. 6, 50 We found no statistical correlation between the expression levels of TRAF2 and the DNA levels of NF-B. This result is not surprising given that NF-B is a key regulator of numerous biological processes other than apoptosis control, such as inflammation and immune response, which can be strongly activated in cancer cells and in which the NF-B activation is controlled through different intracellular signaling mechanisms.
In this study we also investigated the expression of TRAF1, another protein of the TRAF family. Note that TRAF1 was detected in tumor samples but not in normal brain tissue, and such expression tended to increase in cases of augmented nuclear activity of NF-B (p = 0.07). These results are consistent with the current data that TRAF1 is an NF-B-inducible protein. 9, 32, 43, 48 It appears that TRAF1 works in conjunction with TRAF2 and c-IAPs to suppress fully TNF-induced apoptosis. This action may be achieved through the direct suppression of caspase activation in the TNFR signaling complex by c-IAPs, which are specifically recruited through TRAF1 and TRAF2. 18, 33, 48 To develop a comprehensive understanding of the molecular mechanism of TRAF-mediated signals, a number of researchers have been looking for and have identified some proteins that associate with TRAF proteins with a regulatory function. Both TANK 10 and I-TRAF 39 were identified using the yeast two-hybrid system with TRAF3 and TRAF2, respectively, as bait. The I-TRAF and TANK are identical and bind all members of TRAF except TRAF4 through the TRAF-C domain. Note, however, that the function of TANK is not clear due to conflicting results. Data in one report show that TANK and TRAF2 activate NF-B synergistically, whereas those from another study show that TANK apparently inhibits TRAF2-mediated NF-B activation. This discrepancy may result from the experimental conditions but remains to be resolved. 18 We found an inverse correlation between the TANK expression levels and the DNA-binding activity levels of NF-B, and higher TANK expression levels correlated with increased caspase 3 activity. Even though these results were affected by the presence of numerous outliers, the correlations indicate an inhibitory role of such protein in the NF-B activation process in astrocytoma cells. These data agree with those in a recent report on the upregulation of I-TRAF in glioma cell lines after methionine deprivation, a metabolic stress that inhibits mitosis and induces cell cycle arrest and apoptosis. 25 Even the mechanism by which TANK modulates TRAF2 function has not been well defined. One possible mechanism, which is in accordance with our observations, is a competition between TANK and TNFR to bind to overlapping sites within the TRAF domain of TRAF2, indicating that TANK can prevent the association of TRAF2 with the TNF receptor and thus maintaining TRAF2 in a quiescent state in the cytoplasm of unstimulated cells.
Another point that deserves comment is the relationship among caspase 3 activity, tumor histological grade, and NF- cell proliferation, necrosis is considered the hallmark of malignancy; and authors of several studies have correlated the degree of necrosis with a worsened outlook in patients with high-grade gliomas. A switch between apoptosis and necrosis has been proposed, and reportedly a tumor cell's potential for entering apoptosis or necrosis may vary inversely. 2 In both mechanisms TNF plays a pivotal role. Accordingly, the NF-B activation preventing the completion of TNFinduced apoptosis could promote necrosis as the final mode of cell death. We did not find a strict correlation between NF-B and caspase 3 activity. This finding is not surprising given that the NF-B-mediated control of cell survival is only one mechanism of a much more complex regulatory network. Note that it is interesting to observe the results obtained in GBMs; in such tumors, which are typically characterized by tissular necrosis, we recorded higher NF-B, TRAF1, and TRAF2 expression levels and lower caspase 3 and TANK expression levels. Therefore, one can infer that in GBMs there is a switch between apoptosis and necrosis in which NF-B activation may play a role.
Conclusions
Our data indicate that in human gliomas, an increased NF-B DNA-binding activity is present and that such activity may be correlated with tumor malignancy. The TRAF proteins are involved in the intracellular signaling pathways leading from TNFR to the activation of NF-B and the activation of caspases in human gliomas. These signaling steps are tightly interwoven in a network of additional signaling molecules and effectors capable of regulating the overall outcome of the cellular TNF response. In general, TRAF proteins, and especially the TRAF 2 molecule, are at the center of this regulatory network. A detailed understanding of the underlying regulatory processes will finally enable us to predict a specific cellular response initiated by TNF and may therefore improve the handling of the pathophysiological aspects of TNF.
